Curated News
By: NewsRamp Editorial Staff
April 17, 2025
Mayo Clinic's Dr. Howe to Discuss Aditxt's ADI-100 Study
TLDR
- Join Aditxt's Weekly Update on May 2, 2025, to gain insights on ADI-100's preclinical study, giving an edge in the health innovation sector.
- Dr. Charles Howe and Aditxt experts will cover key findings of ADI-100's preclinical study, advancing immune modulation therapy.
- Aditxt's collaborative ecosystem democratizes innovation, driving disruptive growth and addressing societal challenges for a healthier tomorrow.
- Aditxt's upcoming Weekly Update features Dr. Charles Howe discussing ADI-100's preclinical study findings, offering a glimpse into cutting-edge health innovations.
Impact - Why it Matters
This news matters as it showcases the collaboration between Aditxt and Mayo Clinic in advancing immune modulation therapy and developing innovative health solutions. Investors and stakeholders can gain insights into the latest findings in preclinical studies, demonstrating the company's commitment to addressing critical health challenges.
Summary
Aditxt (NASDAQ: ADTX) announced that Dr. Charles Howe of the Mayo Clinic will join the Company’s Weekly Update on May 2, 2025, to discuss key findings from a newly announced preclinical study of ADI-100, the lead therapeutic candidate from Aditxt’s subsidiary, Adimune Inc. The update will also feature Dr. Shahrokh Shabahang, Aditxt’s Chief Innovation Officer, and Dr. Friedrich Kapp, Co-CEO of Adimune, highlighting the latest advancements in immune modulation therapy.
Aditxt is an innovation platform dedicated to accelerating promising health innovations, collaborating with research institutions, industry partners, and shareholders. Aditxt's ecosystem drives its mission of advancing disruptive growth and addressing societal challenges. The company operates programs focusing on immune health, precision health, public health, and women’s health, aiming to discover innovative solutions for urgent health challenges.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Mayo Clinic's Dr. Howe to Discuss Aditxt's ADI-100 Study
